CIM LLC’s Bristol-Myers Squibb BMY Stock Holding History

CIM LLC’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,493	Closed	-$473K	–	112
2020 Q1	$473K	Buy	+8,493	New	+$519K	0.18%	79

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CIM LLC's BMY Position: Q2 2020 in Review

CIM LLC sold out of Bristol-Myers Squibb (BMY) in Q2 2020, closing a stake of 8,493 shares — an estimated $473K sold.

CIM LLC first reported a position in BMY in Q1 2020 and held it in 1 quarter. The position peaked at $473K in Q1 2020. 2,189 funds tracked by Wall St. Rank hold BMY as of Q2 2020.

CIM LLC reported no remaining Bristol-Myers Squibb position as of Q2 2020 after selling out during the quarter.
CIM LLC sold 8,493 Bristol-Myers Squibb shares in Q2 2020, an estimated $473K.
CIM LLC first reported a position in Bristol-Myers Squibb in Q1 2020 and held it in 1 quarter.
CIM LLC's Bristol-Myers Squibb position peaked at $473K in Q1 2020.
2,189 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2020.

Based on CIM LLC's 13F filing for Q2 2020, filed 7 Aug 2020.